Lipocine Inc (LPCN)

$5.23 +0.58 (12.47%)
Market Cap 29.04M
Revenue (ttm) 11.20M
Net Income (ttm) 10,000.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.09%
Debt to Equity Ratio 0.00
Volume 139,500
Avg Vol 59,832
Day's Range N/A - N/A
Shares Out 5.55M
Stochastic %K 99%
Beta 1.03
Analysts Sell
Price Target $6.88

Company Profile

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone...

Industry: Biotechnology
Sector: Healthcare
Phone: 801 994 7383
Fax: 801 994 7388
Address:
675 Arapeen Drive, Suite 202, Salt Lake City, United States
brunoq14
brunoq14 Dec. 27 at 5:43 PM
$LPCN With the multi product potential, including both further development of the lead drug and an extensive pipeline, aren't they likely to be acquired?
1 · Reply
GlobalMarketBulletin
GlobalMarketBulletin Dec. 27 at 8:50 AM
$LPCN With late-stage clinical data on the horizon and a proprietary oral drug delivery platform, Lipocine Inc. (NASDAQ:LPCN) is positioning itself for a potential inflection point in women’s health and CNS treatments. https://globalmarketbulletin.com/lipocine-lpcn-could-be-a-high-risk-high-reward-biotech-heading-into-2026/
1 · Reply
ITF
ITF Dec. 27 at 12:30 AM
$LPCN dilution around 10-12 bucks than down to low 4’s high 3’s till early 2027?thoughts. Everybody wishes for partners and a buyout but let’s be real for the moment
2 · Reply
Geraldbeak
Geraldbeak Dec. 26 at 7:59 PM
$LPCN Be prepared for one more price flush. This has been a low volume run up.
3 · Reply
BioRich
BioRich Dec. 26 at 7:04 PM
$LPCN Quietly climbing impressively. Is this a buy more or simply hold and ride at this point? Cheers!
1 · Reply
Chris_Deil
Chris_Deil Dec. 26 at 6:49 PM
$LPCN I lost hope many many months ago but damm I’m about even now let’s see what will happen here
1 · Reply
hitmongreen
hitmongreen Dec. 26 at 6:24 PM
$LPCN what we doing here??
2 · Reply
GrenadeGains
GrenadeGains Dec. 25 at 9:05 AM
$LPCN Capital discipline has become the critical gating factor, while valuation increasingly tracks execution consistency. Clear follow‑through could unlock sustainable re‑rating.
0 · Reply
HoHoHoHum
HoHoHoHum Dec. 24 at 10:44 AM
$LPCN i am in the green here now. ‘26 is the year for LPCN. We are set up to go!
1 · Reply
JackLewisLPCN
JackLewisLPCN Dec. 24 at 1:01 AM
$LPCN encouraging that this is happening around tax loss harvesting time.
1 · Reply
Latest News on LPCN
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Dec 16, 2025, 8:00 AM EST - 11 days ago

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Nov 18, 2025, 8:00 AM EST - 5 weeks ago

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

Nov 6, 2025, 8:00 AM EST - 7 weeks ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

Nov 4, 2025, 8:00 AM EST - 7 weeks ago

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

Sep 30, 2025, 8:00 AM EDT - 3 months ago

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 4:30 PM EDT - 4 months ago

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

Aug 26, 2025, 8:00 AM EDT - 4 months ago

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

Aug 5, 2025, 8:00 AM EDT - 5 months ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

Jun 26, 2025, 8:00 AM EDT - 6 months ago

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

Jun 23, 2025, 8:00 AM EDT - 6 months ago

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

Jun 9, 2025, 8:00 AM EDT - 7 months ago

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

May 22, 2025, 8:00 AM EDT - 7 months ago

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

May 14, 2025, 8:00 AM EDT - 8 months ago

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

May 8, 2025, 8:00 AM EDT - 8 months ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

May 6, 2025, 8:00 AM EDT - 8 months ago

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Mar 26, 2025, 8:00 AM EDT - 9 months ago

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Mar 13, 2025, 8:00 AM EDT - 10 months ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Lipocine Announces FDA Labeling Changes for Testosterone Products

Mar 12, 2025, 8:00 AM EDT - 10 months ago

Lipocine Announces FDA Labeling Changes for Testosterone Products

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

Feb 6, 2025, 8:00 AM EST - 11 months ago

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Dec 17, 2024, 8:00 AM EST - 1 year ago

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Nov 18, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Oct 10, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

May 9, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

May 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

May 1, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

Mar 7, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

Lipocine to Present at 36th Annual Roth Conference

Mar 6, 2024, 8:00 AM EST - 1 year ago

Lipocine to Present at 36th Annual Roth Conference

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

Feb 6, 2024, 8:00 AM EST - 2 years ago

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals

Feb 2, 2024, 8:00 AM EST - 2 years ago

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

Jan 18, 2024, 8:00 AM EST - 2 years ago

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

Lipocine to Present at Biotech Showcase 2024

Dec 19, 2023, 8:00 AM EST - 2 years ago

Lipocine to Present at Biotech Showcase 2024

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023

Nov 13, 2023, 2:45 PM EST - 2 years ago

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023

Nov 8, 2023, 8:00 AM EST - 2 years ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023

Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023

Nov 1, 2023, 8:00 AM EDT - 2 years ago

Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023

Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression

Oct 26, 2023, 8:00 AM EDT - 2 years ago

Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression

Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference

Oct 23, 2023, 7:00 PM EDT - 2 years ago

Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference

Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference

Sep 19, 2023, 4:05 PM EDT - 2 years ago

Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference

brunoq14
brunoq14 Dec. 27 at 5:43 PM
$LPCN With the multi product potential, including both further development of the lead drug and an extensive pipeline, aren't they likely to be acquired?
1 · Reply
GlobalMarketBulletin
GlobalMarketBulletin Dec. 27 at 8:50 AM
$LPCN With late-stage clinical data on the horizon and a proprietary oral drug delivery platform, Lipocine Inc. (NASDAQ:LPCN) is positioning itself for a potential inflection point in women’s health and CNS treatments. https://globalmarketbulletin.com/lipocine-lpcn-could-be-a-high-risk-high-reward-biotech-heading-into-2026/
1 · Reply
ITF
ITF Dec. 27 at 12:30 AM
$LPCN dilution around 10-12 bucks than down to low 4’s high 3’s till early 2027?thoughts. Everybody wishes for partners and a buyout but let’s be real for the moment
2 · Reply
Geraldbeak
Geraldbeak Dec. 26 at 7:59 PM
$LPCN Be prepared for one more price flush. This has been a low volume run up.
3 · Reply
BioRich
BioRich Dec. 26 at 7:04 PM
$LPCN Quietly climbing impressively. Is this a buy more or simply hold and ride at this point? Cheers!
1 · Reply
Chris_Deil
Chris_Deil Dec. 26 at 6:49 PM
$LPCN I lost hope many many months ago but damm I’m about even now let’s see what will happen here
1 · Reply
hitmongreen
hitmongreen Dec. 26 at 6:24 PM
$LPCN what we doing here??
2 · Reply
GrenadeGains
GrenadeGains Dec. 25 at 9:05 AM
$LPCN Capital discipline has become the critical gating factor, while valuation increasingly tracks execution consistency. Clear follow‑through could unlock sustainable re‑rating.
0 · Reply
HoHoHoHum
HoHoHoHum Dec. 24 at 10:44 AM
$LPCN i am in the green here now. ‘26 is the year for LPCN. We are set up to go!
1 · Reply
JackLewisLPCN
JackLewisLPCN Dec. 24 at 1:01 AM
$LPCN encouraging that this is happening around tax loss harvesting time.
1 · Reply
BioAB
BioAB Dec. 23 at 11:34 PM
$LPCN just keep holding and accumulate
0 · Reply
Tothemoonemoji
Tothemoonemoji Dec. 23 at 10:22 PM
$LPCN Just saw the filing for that fund that owns more than 5 percent now. It says Lipocine is the issuer, does that mean these weren't bought on the open market?
2 · Reply
oneshotstevie
oneshotstevie Dec. 23 at 9:47 PM
$LPCN seems like after hours stop loss raid, anyone know the volume on that drop?
0 · Reply
aah98a
aah98a Dec. 23 at 9:20 PM
$LPCN I am surprised the companies that are tracking LPCN have not provided any recent guidelines! especially with all the recent news (such as Price targets, buy ratings and etc….)! I am loving this run up! Any thoughts on what price we should see the stock price stabilize? or is this going to continue going up for a while? Hopefully someone is smart enough to partner with us. I am rooting for a partner
1 · Reply
DivvyDoo
DivvyDoo Dec. 23 at 8:34 PM
$LPCN New patent: https://ppubs.uspto.gov/api/pdf/downloadPdf/12502396?requestToken=eyJzdWIiOiJiNGI3ZTk4MS0wOTJiLTQyZjEtYmMzZi0wMDAyMTcyYjUyOTQiLCJ2ZXIiOiI5MzczYzJhZS0wZDkxLTQ4N2EtOGE3MC0xMmFkZTNhMmVhNTIiLCJleHAiOjB9
1 · Reply
Pedelco
Pedelco Dec. 23 at 6:05 PM
$LPCN worth it Lipo ?
0 · Reply
RidingUptrends
RidingUptrends Dec. 23 at 1:21 AM
If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. 🚀 Crazy run coming on $INAB $EVTV $NBY $LPCN
0 · Reply
StockScanners
StockScanners Dec. 20 at 6:30 PM
$LPCN reached 4.35
1 · Reply
mattyGLTATTFNBFOT
mattyGLTATTFNBFOT Dec. 19 at 1:51 PM
$LPCN Seems quite early for a “run up.” Trying to make sense of the price movement.
4 · Reply
brunoq14
brunoq14 Dec. 19 at 11:12 AM
$LPCN Great results, as well as rapid enrollment. And I'm suddenly up over 30%. Looks like someone is paying attention.
0 · Reply
JackLewisLPCN
JackLewisLPCN Dec. 18 at 4:02 PM
$LPCN I like the way you're moving, but you've got a ways to go, old friend.
3 · Reply
aah98a
aah98a Dec. 18 at 4:01 PM
$LPCN I really hope we can maintain this momentum. whats a realistic PADUFA date for the phase 3 study?
2 · Reply